EUCTR2012-002840-26-IT进行中（未招募）不适用
A MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PHASE 4 STUDY TO EVALUATE THE EFFICACY OF ROTIGOTINE ON PARKINSON’S DISEASE-ASSOCIATED APATHY, MOTOR SYMPTOMS, AND MOOD
CB BIOSCIENCES GMBH0 个研究点目标入组 600 人开始时间: 2013年1月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. An Institutional Review Board (IRB)/Independent Ethics Committee
- •(IEC) approved written Informed Consent form is signed and dated by
- •the subject. 2. Subject is considered reliable and capable of adhering to the protocol, visit schedule or medication application according to the judgment of the investigator. 3. Subject is male or female and = 18 years old at the Screening Visit. 4. Subject has idiopathic Parkinson's disease, defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following:
- •resting tremor, rigidity, or impairment of postural reflexes, and without any other known or suspected cause of parkinsonism. 5. Subject has unsatisfactory control of Parkinson's disease motor symptoms under the current treatment, according to the judgment of the investigator.
- •6. Subject has a Hoehn and Yahr stage score I-IV during the on state
- •at the Screening Visit.7. If subject is taking levodopa, he/she must be on a stable dose of levodopa (in combination with benserazide or carbidopa) for at least 28
- •days prior to the Baseline Visit, and the dose is expected to be maintained for the duration of the study. 8. Subject suffers from apathy associated with Parkinson's disease for at least 3 months, evidenced by a score of = 2 on UPDRS Part I Item 4 at
- •the Screening Visit and an average of at least = 14 on the AS at the Screening and Baseline Visit as rated by the subject.
- •9. Subject has a Mini-Mental State Examination (MMSE) score = 25 at the
- •Screening Visit.10. If the subject is receiving an anticholinergic agent, a monoamineoxidase (MAO) B-inhibitor, the Catechol-O-Methyl Transferase (COMT)inhibitor entacapone, or the N Methyl D Aspartate (NMDA) antagonist
- •amantadine, he/she must have been on a stable dose for at least 28 days prior to the Baseline Visit, and the dose is expected to be maintained for the duration of the study. 11. If subject is taking an antidepressant drug, such as selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine
- •reuptake inhibitors (SNRIs), bupropion, or tricyclic antidepressants (TCAs), he/she must have been on a stable dose for at least 28 days prior to the Baseline Visit, and the dose is expected to be maintained for the duration of the study.
- •12. Female subjects must be either postmenopausal for at least 1 year,
- •surgically incapable of childbearing, or effectively practicing an acceptable method of contraception (either oral/parenteral/implantable
- •hormonal contraceptives, intrauterine device, or barrier and spermicide).
- •Abstinence only is not an acceptable method. Subjects must agree to use
- •adequate contraception during the study and for 4 weeks after their final
- •dose of rotigotine (or longer, if required by local regulations).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 400
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •1.Subject has previously participated in this study or subject has previously been assigned to treatment in a study of the medication under investigation in this study. 2.Subject has participated in another study of an investigational medicinal product (IMP) or a medical device within the last 28 days prior to the Screening Visit or is currently participating in another study of an IMP or a medical device. 3. Subject has had prior therapy with a dopamine agonist within 28 days prior to the Baseline Visit. 4.Subject discontinued from previous therapy with a dopamine agonist after an adequate length of treatment, at an adequate dose, due to lack of efficacy as assessed by the investigator. 5.Subject has a history of chronic alcohol or drug abuse within the last 6 months. 6.Subject has any medical or psychiatric condition (ie, bipolar disorder, dementia, hallucinations, or psychosis) that, in the opinion of the investigator, could jeopardize or would compromise the subject’s ability to participate in this study. 7.Subject has received neuroleptics (except clozapine and quetiapine), dopamine releasing substances (eg, methylphenidate or amphetamine), dopamine modulating substances (eg, reserpine), alpha-methyldopa, metoclopramide, MAO-A inhibitors, budipine, or tolcapone within 28 days of the Baseline Visit. 8. Subject has received electroconvulsive therapy within 12 weeks prior to the Screening Visit. 9. Subject is receiving current psychotherapy or behavior therapy while participating in this study. 10. Subject has a history of deep brain stimulation. 11.Subject has a known hypersensitivity to any components of the IMP or comparative drugs as stated in the protocol. 12. Subject has a significant skin disease that would make transdermal drug use inappropriate, including a history of skin sensitivity to adhesives or transdermal medications. 13. Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response (Yes”) to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the Screening Visit. 14. Subject has an atypical Parkinson’s disease syndrome due to drugs (eg, neuroleptics, metoclopramide, flunarizine), metabolic neurogenetic disorders (eg, Wilson Disease), encephalitis, cerebrovascular disease, or degenerative diseases (progressive supranuclear palsy). 15. Subject has evidence of an impulse control disorder (ICD) according to the modified Minnesota Impulsive Disorders Interview (mMIDI) at the Screening Visit confirmed by a positive structured clinical interview. 16.Subject who is currently lactating or pregnant or planning to become pregnant during the duration of the study. 17. Subject diagnosed with severe depression as evidenced by a BDI-II score of =29 at the Screening Visit. 18Subject has symptomatic orthostatic hypotension at Screening.
研究者
相似试验
进行中（未招募）
不适用
A DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PLACEBO-CONTROLLED 10-WEEK STUDY ASSESSING THE EFFICACY AND SAFETY OF F2695 SR FLEXIBLE DOSE (75,100 MG /DAY) IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER EFFICACY AND TOLERANCE OF F2695 SR IN MAJOR DEPRESSIVE DISORDERMajor Depressive DisorderEUCTR2006-002404-34-CZPierre Fabre Médicament534
进行中（未招募）
不适用
A DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PLACEBO-CONTROLLED 10-WEEK STUDY ASSESSING THE EFFICACY AND SAFETY OF F2695 SR FLEXIBLE DOSE (75,100 MG /DAY) IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER EFFICACY AND TOLERANCE OF F2695 SR IN MAJOR DEPRESSIVE DISORDERMajor Depressive DisorderEUCTR2006-002404-34-EEPierre Fabre Médicament534
进行中（未招募）
1 期
A DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PLACEBO-CONTROLLED 10-WEEK STUDY ASSESSING THE EFFICACY AND SAFETY OF F2695 SR FLEXIBLE DOSE (75,100 MG /DAY) IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDERMedDRA version: 8.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive DisorderEUCTR2006-002404-34-DEPierre Fabre Médicament534
进行中（未招募）
不适用
A DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PLACEBO-CONTROLLED 10-WEEK STUDY ASSESSING THE EFFICACY AND SAFETY OF F2695 SR FLEXIBLE DOSE (75,100 MG /DAY) IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER EFFICACY AND TOLERANCE OF F2695 SR IN MAJOR DEPRESSIVE DISORDERMajor Depressive DisorderEUCTR2006-002404-34-LVPierre Fabre Médicament534
进行中（未招募）
不适用
A DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PLACEBO-CONTROLLED 10-WEEK STUDY ASSESSING THE EFFICACY AND SAFETY OF F2695 SR FLEXIBLE DOSE (75,100 MG /DAY) IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER EFFICACY AND TOLERANCE OF F2695 SR IN MAJOR DEPRESSIVE DISORDERMedDRA version: 8.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive DisorderEUCTR2006-002404-34-SEPierre Fabre Médicament534